Value of BNP and tumour marker CA125 in patients with heart failure

Chen, Yangxin; Wang, Xiaoqiao; Fang, Chongfeng; Wang, Jingfeng; Tang, Lijiang

doi:10.2143/ac.63.4.2033050

Cited by 55 publications

(49 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared to those with CA 125 ≤ 5 U/ml, patients with CA 125 > 35 U/ml had higher serum levels of NT-proBNP and worse echocardiographic and haemodynamic parameters at baseline. In all 5 Cox models we constructed, CA125 > 35 U/ml was associated with an over 2-fold increased risk of 1-year clinical worsening, which was similar to the results seen in heart failure ( 32 , 33 ). Furthermore, ROC analysis showed that CA 125 provided additional predictive value in addition to the established PH biomarker NT-proBNP ( 18 ).…”

Section: Discussionsupporting

confidence: 65%

Carbohydrate Antigen 125 Is a Biomarker of the Severity and Prognosis of Pulmonary Hypertension

Zhang

Jin

Zhao

et al. 2021

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Background: Emerging evidence has showed that serum carbohydrate antigen 125 (CA 125) levels are associated with the severity and prognosis of heart failure. However, its role in pulmonary hypertension remains unclear. This study aimed to investigate the clinical, echocardiographic, hemodynamic, and prognostic associations of CA 125 in pulmonary hypertension.Methods and Results: We conducted a retrospective cohort study of all idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension patients receiving CA 125 measurement in Fuwai Hospital (January 1, 2014–December 31, 2018). The primary end-point was cumulative 1-year clinical worsening-free survival rate. Linear regression was performed to assess the association between CA 125 and clinical, echocardiographic, and hemodynamic parameters. Cox proportional hazards models were used to assess the association between CA 125 and clinical worsening events. Receiver operating characteristic (ROC) curve analysis was performed to determine the predictive performance of CA 125. A total of 231 patients were included. After adjustment, CA 125 still positively correlated with World Health Organization functional class, NT-proBNP, right ventricular end-diastolic diameter, pericardial effusion, mean right atrial pressure and pulmonary arterial wedge pressure; negatively correlated with 6-min walk distance, left ventricular end-diastolic diameter, mixed venous oxygen saturation, and cardiac index. After adjustment, CA 125 > 35 U/ml was associated with over 2 folds increased risk of 1-year clinical worsening. Further, ROC analysis showed that CA 125 provided additional predictive value in addition to the established pulmonary hypertension biomarker NT-proBNP.Conclusion: CA 125 was associated with functional status, echocardiography, hemodynamics and prognosis of pulmonary hypertension.

show abstract

Section: Discussionsupporting

confidence: 65%

Carbohydrate Antigen 125 Is a Biomarker of the Severity and Prognosis of Pulmonary Hypertension

Zhang

Jin

Zhao

et al. 2021

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…The heterojunctions on the interface could provide an internal electric field to improve the surface reaction electrodynamics and facilitate electron/ion transport. 36,37 Successively, the pore size distributions of OMC-g-MXene heterostructure and etched MXene are comprehensively investigated by nitrogen adsorption−desorption isothermal curves (Figure S4). With the modification of OMC, the specific surface areas of OMC-g-MXene heterostructure is calculated to be 202.36 m 2 g −1 , which is much larger than that of densely packed MXene (17.52 m 2 g −1 ).…”

Section: Resultsmentioning

confidence: 99%

Ordered Mesoporous Carbon Grafted MXene Catalytic Heterostructure as Li-Ion Kinetic Pump toward High-Efficient Sulfur/Sulfide Conversions for Li–S Battery

et al. 2023

View full text Add to dashboard Cite

Lithium–sulfur (Li–S) batteries exhibit unparalleled theoretical capacity and energy density than conventional lithium ion batteries, but they are hindered by the dissatisfactory “shuttle effect” and the sluggish conversion kinetics owing to the low lithium ion transport kinetics, resulting in rapid capacity fading. Herein, a catalytic two-dimensional heterostructure composite is prepared by evenly grafting mesoporous carbon on the MXene nanosheet (denoted as OMC-g-MXene), serving as interfacial kinetic accelerators in Li–S batteries. In this design, the grafted mesoporous carbon in the heterostructure can not only prevent the stack of MXene nanosheets with the enhanced mechanical property but also offer a facilitated pump for accelerating ion diffusion. Meanwhile, the exposed defect-rich OMC-g-MXene heterostructure inhibits the polysulfide shuttling with chemical interactions between OMC-g-MXene and polysulfides and thus simultaneously enhances the electrochemical conversion kinetics and efficiency, as fully investigated by in situ/ex situ characterizations. Consequently, the cells with OMC-g-MXene ion pumps achieve a high cycling capacity (966 mAh g–1 at 0.2 C after 200 cycles), a superior rate performance (537 mAh g–1 at 5 C), and an ultralow decaying rate of 0.047% per cycle after 800 cycles at 1 C. Even employed with a high sulfur loading of 7.08 mg cm–2 under lean electrolyte, an ultrahigh areal capacity of 4.5 mAh cm–2 is acquired, demonstrating a future practical application.

show abstract

“…The predictive value for all-cause mortality up to 6-months after index HF hospitalization had also been demonstrated by the same study group [22]. On the other hand, there also seems to be a moderate correlation between CA-125 and brain natriuretic peptide (BNP) level, the most commonly used biomarker reflecting degree of excessive ventricular wall stress, hemodynamics or ventricular filling abnormalities in left-sided HF [23,24]. Interestingly, though both markers had been reported to rise in acute heart failure, combination of them in clinical use may further improve risk stratification at follow up [23,25].…”

Section: Brief Introductionmentioning

confidence: 82%

Beyond malignancy: the role of carbohydrate antigen 125 in heart failure

Hung

Lai

et al. 2013

Biomark Res

View full text Add to dashboard Cite

Carbohydrate antigen 125 (CA-125), traditionally a tumor marker for screening, diagnosis, and monitoring in ovarian malignancy, had recently been shown increasing evidence and more extensively recognized/explored as a novel surrogate of heart failure (HF). The exact mechanisms underlying the pathophysiologic link between elevated serum CA-125 concentration and HF may be multi-factorial, with both mechanical and inflammatory process including numerous potential cytokines involved. Accumulating data had consistently indicated its diagnostic and prognostic role in HF patients in various clinical settings, however, there is limited clinical information regarding the incremental value or head-to-head comparison of such marker to other well-established HF markers. In this brief review, we aimed to discuss the biosynthesis, and potential insights of underlying pathophysiologies associated with CA-125 secretion in the scenarios of cardiac structural/functional alterations and HF, and further explored its current usage and roles in several recent reports.

show abstract

Value of BNP and tumour marker CA125 in patients with heart failure

Cited by 55 publications

References 18 publications

Carbohydrate Antigen 125 Is a Biomarker of the Severity and Prognosis of Pulmonary Hypertension

Carbohydrate Antigen 125 Is a Biomarker of the Severity and Prognosis of Pulmonary Hypertension

Ordered Mesoporous Carbon Grafted MXene Catalytic Heterostructure as Li-Ion Kinetic Pump toward High-Efficient Sulfur/Sulfide Conversions for Li–S Battery

Beyond malignancy: the role of carbohydrate antigen 125 in heart failure

Contact Info

Product

Resources

About